

Naji Tabet

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4336975/publications.pdf>

Version: 2024-02-01

79
papers

3,521
citations

257450

24
h-index

155660

55
g-index

84
all docs

84
docs citations

84
times ranked

5424
citing authors

#	ARTICLE	IF	CITATIONS
1	Sensitivity and specificity of dopamine transporter imaging with ¹²³ I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. <i>Lancet Neurology</i> , The, 2007, 6, 305-313.	10.2	598
2	Microbes and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 51, 979-984.	2.6	426
3	Aerobic exercise to improve cognitive function in older people without known cognitive impairment. <i>The Cochrane Library</i> , 2015, 2015, CD005381.	2.8	271
4	Vitamin E for Alzheimer's dementia and mild cognitive impairment. <i>The Cochrane Library</i> , 2017, 4, CD002854.	2.8	176
5	An educational intervention can prevent delirium on acute medical wards. <i>Age and Ageing</i> , 2005, 34, 152-156.	1.6	167
6	The effect of exercise interventions on cognitive outcome in Alzheimer's disease: a systematic review. <i>International Psychogeriatrics</i> , 2014, 26, 9-18.	1.0	158
7	Efficacy of Antidepressants for Depression in Alzheimer's Disease: Systematic Review and Meta-Analysis. <i>Journal of Alzheimer's Disease</i> , 2017, 58, 725-733.	2.6	140
8	To tell or not to tell? comparison of older patients' reaction to their diagnosis of dementia and depression. <i>International Journal of Geriatric Psychiatry</i> , 2001, 16, 879-885.	2.7	97
9	Vitamin E for Alzheimer's disease and mild cognitive impairment. , 2008, , CD002854.		94
10	Positive Effects of Cholinergic Stimulation Favor Young APOE ε4 Carriers. <i>Neuropsychopharmacology</i> , 2010, 35, 1090-1096.	5.4	79
11	Vitamin and mineral supplementation for preventing dementia or delaying cognitive decline in people with mild cognitive impairment. <i>The Cochrane Library</i> , 2019, 2019, CD011905.	2.8	78
12	Vitamin and mineral supplementation for maintaining cognitive function in cognitively healthy people in mid and late life. <i>The Cochrane Library</i> , 2019, 2019, CD011906.	2.8	77
13	Cognitive and neural signatures of the APOE E4 allele in mid-aged adults. <i>Neurobiology of Aging</i> , 2014, 35, 1615-1623.	3.1	71
14	Slowing the progression of Alzheimer's disease; what works?. <i>Ageing Research Reviews</i> , 2015, 23, 193-209.	10.9	71
15	Vitamin E for Alzheimer's dementia and mild cognitive impairment. , 2017, 1, CD002854.		63
16	Social networks and loneliness in people with Alzheimer's dementia. <i>International Journal of Geriatric Psychiatry</i> , 2019, 34, 666-673.	2.7	55
17	Clinical usefulness of dopamine transporter SPECT imaging with ¹²³ I-FP-CIT in patients with possible dementia with Lewy bodies: Randomised study. <i>British Journal of Psychiatry</i> , 2015, 206, 145-152.	2.8	52
18	Pharmacological treatment for the prevention of delirium: review of current evidence. <i>International Journal of Geriatric Psychiatry</i> , 2009, 24, 1037-1044.	2.7	48

#	ARTICLE	IF	CITATIONS
19	Is Sleep Disruption a Risk Factor for Alzheimer's Disease?. <i>Journal of Alzheimer's Disease</i> , 2017, 58, 993-1002.	2.6	43
20	Structural and resting-state MRI detects regional brain differences in young and mid-age healthy APOE ϵ 4 carriers compared with non-APOE ϵ 4 carriers. <i>NMR in Biomedicine</i> , 2016, 29, 614-624.	2.8	42
21	Non-pharmacological interventions in the prevention of delirium. <i>Age and Ageing</i> , 2009, 38, 374-379.	1.6	39
22	Homocysteine concentrations in the cognitive progression of Alzheimer's disease. <i>Experimental Gerontology</i> , 2017, 99, 146-150.	2.8	36
23	Plasma Fetuin-A is Associated with the Severity of Cognitive Impairment in Mild-to-Moderate Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2011, 24, 327-333.	2.6	31
24	Antioxidant Enzymatic Activities in Alzheimer's Disease: The Relationship to Acetylcholinesterase Inhibitors. <i>Journal of Alzheimer's Disease</i> , 2012, 30, 467-474.	2.6	31
25	Study of mirtazapine for agitated behaviours in dementia (SYMBAD): a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2021, 398, 1487-1497.	13.7	31
26	Vitamins, Trace Elements, and Antioxidant Status in Dementia Disorders. <i>International Psychogeriatrics</i> , 2001, 13, 265-275.	1.0	29
27	The Elusive Nature of APOE ϵ 4 in Mid-adulthood: Understanding the Cognitive Profile. <i>Journal of the International Neuropsychological Society</i> , 2017, 23, 239-253.	1.8	24
28	Knowledge and attitudes towards dementia in adolescent students. <i>Journal of Mental Health</i> , 2017, 26, 419-425.	1.9	24
29	Amyloid-specific T-cells differentiate Alzheimer's disease from Lewy body dementia. <i>Neurobiology of Aging</i> , 2012, 33, 2599-2611.	3.1	22
30	MRI of carriers of the apolipoprotein E ϵ 4 allele—evidence for structural differences in normal-appearing brain tissue in ϵ 4+ relative to ϵ 4- young adults. <i>NMR in Biomedicine</i> , 2013, 26, 674-682.	2.8	22
31	Psychometric properties and feasibility of use of dementia specific quality of life instruments for use in care settings: a systematic review. <i>International Psychogeriatrics</i> , 2021, 33, 917-931.	1.0	21
32	Endogenous Antioxidant Activities in Relation to Concurrent Vitamins A, C, and E Intake in Dementia. <i>International Psychogeriatrics</i> , 2002, 14, 7-15.	1.0	20
33	APOE E4 Carriers Show Prospective Memory Enhancement Under Nicotine, and Evidence for Specialisation Within Medial BA10. <i>Neuropsychopharmacology</i> , 2013, 38, 655-663.	5.4	19
34	Herpes simplex encephalitis and Alzheimer's disease: Is there a link?. <i>Journal of the Neurological Sciences</i> , 2017, 380, 20-21.	0.6	18
35	Blood pro-inflammatory cytokines in Alzheimer's disease in relation to the use of acetylcholinesterase inhibitors. <i>International Journal of Geriatric Psychiatry</i> , 2013, 28, 1312-1317.	2.7	16
36	Diabetic Peripheral Microvascular Complications: Relationship to Cognitive Function. <i>Cardiovascular Psychiatry and Neurology</i> , 2011, 2011, 1-7.	0.8	15

#	ARTICLE	IF	CITATIONS
37	The relationship between habitual physical activity status and executive function in individuals with Alzheimer's disease: a longitudinal, cross-lagged panel analysis. <i>Aging, Neuropsychology, and Cognition</i> , 2016, 23, 234-252.	1.3	15
38	Mid age APOE ϵ 4 carriers show memory-related functional differences and disrupted structure-function relationships in hippocampal regions. <i>Scientific Reports</i> , 2020, 10, 3110.	3.3	15
39	Evolution of clinical features in possible DLB depending on FP-CIT SPECT result. <i>Neurology</i> , 2016, 87, 1045-1051.	1.1	14
40	Disrupted neural activity patterns to novelty and effort in young adult ϵ 4 carriers performing a subsequent memory task. <i>Brain and Behavior</i> , 2017, 7, e00612.	2.2	14
41	Changes of renin-angiotensin system-related aminopeptidases in early stage Alzheimer's disease. <i>Experimental Gerontology</i> , 2017, 89, 1-7.	2.8	13
42	Low 25OH Vitamin D2 Levels Found in Untreated Alzheimer's Patients, Compared to Acetylcholinesterase-Inhibitor Treated and Controls. <i>Current Alzheimer Research</i> , 2012, 9, 1069-1076.	1.4	12
43	Habitual physical activity (HPA) as a factor in sustained executive function in Alzheimer-type dementia: A cohort study. <i>Archives of Gerontology and Geriatrics</i> , 2014, 59, 91-97.	3.0	12
44	Putting attention in the spotlight: The influence of APOE genotype on visual search in mid adulthood. <i>Behavioural Brain Research</i> , 2017, 334, 97-104.	2.2	12
45	Prospective memory in Alzheimer-type dementia: Exploring prospective memory performance in an age-stratified sample. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2013, 35, 983-992.	1.3	11
46	The APOE paradox: do attentional control differences in mid-adulthood reflect risk of late-life cognitive decline. <i>Neurobiology of Aging</i> , 2016, 48, 114-121.	3.1	11
47	Covid-19 and the quality of life of people with dementia and their carers – The TFD-C19 study. <i>PLoS ONE</i> , 2022, 17, e0262475.	2.5	11
48	Vitamin and mineral supplementation for prevention of dementia or delaying cognitive decline in people with mild cognitive impairment. <i>The Cochrane Library</i> , 0, , .	2.8	10
49	Adaptation of the DEMQOL-Proxy for routine use in care homes: a cross-sectional study of the reliability and validity of DEMQOL-CH. <i>BMJ Open</i> , 2019, 9, e028045.	1.9	10
50	Bilingualism: A Global Public Health Strategy for Healthy Cognitive Aging. <i>Frontiers in Neurology</i> , 2021, 12, 628368.	2.4	10
51	Minocycline 200 mg or 400 mg versus placebo for mild Alzheimer's disease: the MADE Phase II, three-arm RCT. <i>Efficacy and Mechanism Evaluation</i> , 2020, 7, 1-62.	0.7	10
52	Higher fat and carbohydrate intake in dementia patients is associated with increased blood glutathione peroxidase activity. <i>International Psychogeriatrics</i> , 2005, 17, 91-98.	1.0	9
53	Prevention, diagnosis and treatment of delirium: staff educational approaches. <i>Expert Review of Neurotherapeutics</i> , 2006, 6, 741-751.	2.8	9
54	Antihypertensives, angiotensin, glucose and Alzheimer's disease. <i>Expert Review of Neurotherapeutics</i> , 2013, 13, 477-482.	2.8	9

#	ARTICLE	IF	CITATIONS
55	Vitamin and mineral supplementation for maintaining cognitive function in cognitively healthy people in mid life. The Cochrane Library, 2015, , .	2.8	9
56	Long-Term High-Effort Endurance Exercise in Older Adults: Diminishing Returns for Cognitive and Brain Aging. Journal of Aging and Physical Activity, 2016, 24, 659-675.	1.0	9
57	In vivo Dopamine Pre-Synaptic Receptors and Antioxidant Activities in Patients with Alzheimer's Disease, Dementia with Lewy Bodies and in Controls. Dementia and Geriatric Cognitive Disorders, 2003, 16, 46-51.	1.5	8
58	Male gender influences response to an educational package for delirium prevention among older people: a stratified analysis. International Journal of Geriatric Psychiatry, 2006, 21, 493-497.	2.7	8
59	Homocysteine in Alzheimer's disease: role of dietary folate, vitamin B6 and B12. International Journal of Geriatric Psychiatry, 2011, 26, 876-877.	2.7	8
60	Nicotine effects on attentional reorienting in mid-age adults, and interactions with apolipoprotein E status. Journal of Psychopharmacology, 2013, 27, 1007-1014.	4.0	8
61	Pro-Inflammatory Cytokines IL-1 β and TNF- α are not Associated with Plasma Homocysteine Concentration in Alzheimer's Disease. Current Alzheimer Research, 2013, 10, 174-179.	1.4	8
62	Vitamin and mineral supplementation for maintaining cognitive function in cognitively healthy people in late life. The Cochrane Library, 2015, , .	2.8	7
63	Vitamin and herbal extracts use in patients diagnosed with dementia: What do health professionals know and think?. Aging and Mental Health, 2011, 15, 267-271.	2.8	6
64	Are symptoms of insomnia in primary care associated with subsequent onset of dementia? A matched retrospective case-control study. Aging and Mental Health, 2020, 24, 1466-1471.	2.8	6
65	Impaired Renal Function and Biomarkers of Vascular Disease in Alzheimer's Disease. Current Alzheimer Research, 2014, 11, 253-258.	1.4	6
66	The Use of a Computerized Cognitive Assessment to Improve the Efficiency of Primary Care Referrals to Memory Services: Protocol for the Accelerating Dementia Pathway Technologies (ADePT) Study. JMIR Research Protocols, 2022, 11, e34475.	1.0	5
67	What factors have influenced quality of life in people with dementia and their family carers during the COVID-19 pandemic: a qualitative study. BMJ Open, 2022, 12, e053563.	1.9	5
68	Using event-related fMRI to examine sustained attention processes and effects of APOE ϵ 4 in young adults. PLoS ONE, 2018, 13, e0198312.	2.5	4
69	Dietary and endogenous antioxidants in dementia. International Journal of Geriatric Psychiatry, 2001, 16, 639-641.	2.7	3
70	Prospective Memory: Age related change is influenced by APOE genotype. Aging, Neuropsychology, and Cognition, 2020, 27, 710-728.	1.3	3
71	Obesity in middle age and future risk of dementia: Dietary fat and sugar may hold the clue. BMJ: British Medical Journal, 2005, 331, 454.3-455.	2.3	3
72	Meige's syndrome in dementia with Lewy bodies. Journal of the Royal Society of Medicine, 2002, 95, 201-202.	2.0	2

#	ARTICLE	IF	CITATIONS
73	Cambridge Cognitive Examination and Hachinski Ischemic Score as predictors of MRI confirmed pathology in dementia: A cross-sectional study. International Journal of Clinical Practice, 2020, 74, e13446.	1.7	1
74	O4-06-03: PREVALENCE OF DLB FEATURES IN POSSIBLE DEMENTIA WITH LEWY BODIES AND ITS RELATIONSHIP TO CHANGES IN DEMENTIA DIAGNOSTIC CATEGORY AFTER DOPAMINE TRANSPORTER IMAGING USING DATSCAN, ., 2014, 10, P262-P262.		0
75	Authors' reply. British Journal of Psychiatry, 2015, 207, 364-365.	2.8	0
76	ICâ€Pâ€021: Impact of ¹⁸ F-Florbetapir Petâ€CT on Clinical Diagnosis and Management of Patients With Possible Alzheimerâ€™s Disease. Alzheimer's and Dementia, 2016, 12, P25.	0.8	0
77	P3-228: Impact of 18 F- Florbetapir PET-CT on Clinical Diagnosis and Management of Patients with Possible Alzheimerâ€™S Disease. , 2016, 12, P912-P913.		0
78	[P1â€“007]: PROSPECTIVE MEMORY: AGEâ€RELATED CHANGES ARE INFLUENCED BY <i>APOE</i> GENOTYPE. Alzheimer's and Dementia, 2017, 13, P233.	0.8	0
79	[P1â€“490]: PROSPECTIVE MEMORY: AGEâ€RELATED CHANGES ARE INFLUENCED BY <i>APOE</i> GENOTYPE. Alzheimer's and Dementia, 2017, 13, P477.	0.8	0